You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 295 No. 5, February 1, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Clinical Review
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (71)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Tobacco
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

CLINICIAN’S CORNER
Medical Treatment of Peripheral Arterial Disease

Graeme J. Hankey, MD; Paul E. Norman, DS; John W. Eikelboom, MBBS, MSc

JAMA. 2006;295:547-553.

Context  Peripheral arterial disease (PAD) affects approximately 20% of adults older than 55 years and is a powerful predictor of myocardial infarction, stroke, and death due to vascular causes. The goals of treatment are to prevent future major coronary and cerebrovascular events and improve leg symptoms.

Objective  To review the best evidence for medical treatment of PAD.

Evidence Acquisition  MEDLINE and the Cochrane database were searched from 1990 to November 2005 for randomized trials and meta-analyses of medical treatments for PAD. References from these articles were also searched. Search terms included, singly and in combination: peripheral arterial disease, peripheral artery disease, PAD, randomized controlled trial, controlled trial, randomized, and meta-analysis. Particular attention was directed toward randomized controlled trials and meta-analyses of clinically relevant medical treatments for PAD. Outcome measures included leg symptoms (intermittent claudication and walking distance), death, and major coronary and cerebrovascular events.

Evidence Synthesis  Symptoms of leg claudication, walking distance, and quality of life can be improved by smoking cessation (physician advice, nicotine replacement therapy, and bupropion), a structured exercise program, statin drugs, cilostazol, and angiotensin-converting enzyme inhibitors. The risk of major coronary and cerebrovascular events can be reduced through lowering blood pressure with angiotensin-converting enzyme inhibitors and other antihypertensive drugs, use of statin drugs, antiplatelet therapy with aspirin or clopidogrel, and probably by stopping smoking.

Conclusion  The substantial and increasing burden of PAD, and its local and systemic complications, can be reduced by lifestyle modification (smoking cessation, exercise) and medical therapies (nicotine replacement therapy, bupropion, antihypertensive drugs, statins, and antiplatelet drugs).


Author Affiliations: Department of Neurology, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth (Dr Hankey); School of Surgery and Pathology, University of Western Australia (Dr Norman); and Department of Medicine, McMaster University, Hamilton, Ontario (Dr Eikelboom).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Medical Management of Peripheral Arterial Disease
Daniel G. Hackam
JAMA. 2006;296(1):41.
EXTRACT | FULL TEXT  

Medical Management of Peripheral Arterial Disease
Thomas E. Finucane
JAMA. 2006;296(1):41.
EXTRACT | FULL TEXT  

Medical Management of Peripheral Arterial Disease—Reply
John Eikelboom, Graeme Hankey, and Paul Norman
JAMA. 2006;296(1):41-42.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Does the Clinical Examination Predict Lower Extremity Peripheral Arterial Disease?
Nadia A. Khan, Sherali A. Rahim, Sonia S. Anand, David L. Simel, and Akbar Panju
JAMA. 2006;295(5):536-546.
ABSTRACT | FULL TEXT  

Peripheral Arterial Disease
Lise M. Stevens, Cassio Lymn, and Richard M. Glass
JAMA. 2006;295(5):584.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Field Synopsis and Meta-Analysis of Genetic Association Studies in Peripheral Arterial Disease: The CUMAGAS-PAD Database
Zintzaras and Zdoukopoulos
Am J Epidemiol 2009;170:1-11.
ABSTRACT | FULL TEXT  

Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease: A Meta-analysis of Randomized Trials
Berger et al.
JAMA 2009;301:1909-1919.
ABSTRACT | FULL TEXT  

Treatment of intermittent claudication
Karthikeyan and Eikelboom
BMJ 2009;338:b46-b46.
FULL TEXT  

Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data
De Backer et al.
BMJ 2009;338:b603-b603.
ABSTRACT | FULL TEXT  

Ethnicity and peripheral artery disease
Bennett et al.
QJM 2009;102:3-16.
ABSTRACT | FULL TEXT  

Effects of Cilostazol and Pentoxifylline on Forearm Reactive Hyperemia Response, Lipid Profile, Oxidative Stress, and Inflammatory Markers in Patients With Intermittent Claudication
de Albuquerque et al.
ANGIOLOGY 2008;59:549-558.
ABSTRACT  

Cardiovascular disease risk in adolescent smokers: evidence of a `smoker lifestyle'
Flouris et al.
J Child Health Care 2008;12:221-231.
ABSTRACT  

A biomarker panel for peripheral arterial disease
Fung et al.
Vasc Med 2008;13:217-224.
ABSTRACT  

Management of Peripheral Arterial Disease
Steffen et al.
Diabetes Spectr. 2008;21:171-177.
ABSTRACT | FULL TEXT  

Effects of Policosanol (10 mg/d) Versus Aspirin (100 mg/d) in Patients With Intermittent Claudication: A 10-Week, Randomized, Comparative Study
Illnait et al.
ANGIOLOGY 2008;59:269-277.
ABSTRACT  

Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Sobel and Verhaeghe
Chest 2008;133:815S-843S.
ABSTRACT | FULL TEXT  

Therapeutic Angiogenesis Using Tissue Engineered Human Smooth Muscle Cell Sheets
Hobo et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:637-643.
ABSTRACT | FULL TEXT  

Prescribing Practice of General Practitioners in Northern Ireland for Peripheral Arterial Disease
Badger et al.
ANGIOLOGY 2008;59:57-63.
ABSTRACT  

Buflomedil in Peripheral Arterial Disease: Trials and Tribulations
Conte
Circulation 2008;117:717-719.
FULL TEXT  

Oral Buflomedil in the Prevention of Cardiovascular Events in Patients With Peripheral Arterial Obstructive Disease: A Randomized, Placebo-Controlled, 4-Year Study
Limbs International Medicinal Buflomedil (LIMB) St
Circulation 2008;117:816-822.
ABSTRACT | FULL TEXT  

Ankle-to-Brachial Index and Dementia: The Honolulu-Asia Aging Study
Laurin et al.
Circulation 2007;116:2269-2274.
ABSTRACT | FULL TEXT  

{beta}2-Microglobulin as a Biomarker in Peripheral Arterial Disease: Proteomic Profiling and Clinical Studies
Wilson et al.
Circulation 2007;116:1396-1403.
ABSTRACT | FULL TEXT  

Current Treatment of Peripheral Arterial Disease: Role of Percutaneous Interventional Therapies
Mahmud et al.
J Am Coll Cardiol 2007;50:473-490.
ABSTRACT | FULL TEXT  

PERIPHERAL VASCULAR DISEASE IN DIABETIC PERITONEAL DIALYSIS PATIENTS
Saha et al.
pdi 2007;27:S210-S214.
ABSTRACT | FULL TEXT  

Intermittent Claudication
White
NEJM 2007;356:1241-1250.
FULL TEXT  

Increasing Survival of Ischemic Tissue by Targeting CD47
Isenberg et al.
Circ. Res. 2007;100:712-720.
ABSTRACT | FULL TEXT  

Medical management of peripheral arterial disease.
Hackam
JAMA 2006;296:41-41.
FULL TEXT  

Medical management of peripheral arterial disease.
Finucane
JAMA 2006;296:41-41.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.